Banking giant massively resets Jazz Pharma stock price target

Changes in Wall Street price targets usually arrive in small increments. A few dollars up, a few dollars down, and sometimes a rating left untouched.

UBS skipped that script with Jazz Pharmaceuticals (JAZZ).

On May 19, UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals two notches, from neutral straight to buy, and lifted his price target to $307 from $188. That is a 63% jump in one move, and it sits well above the prior analyst consensus of roughly $242.

For a stock that has already climbed 39% year to date and more than 100% over the past year, that kind of reset is worth a closer look.

Why UBS raised its Jazz Pharma stock price target now

Timing is what separates this call from a routine upgrade.

Verma’s target reset lands just ahead of an August 25 PDUFA date for zanidatamab, sold as Ziihera, in first-line HER2-positive gastroesophageal cancer. A PDUFA date is the deadline the FDA sets to decide whether to approve a drug, so it serves as a hard catalyst investors can mark on a calendar.

UBS expects that approval to drive a faster commercial ramp than the market assumes. The firm projects around $3.1 billion in peak Ziihera sales, helped by strong Phase 3 HERIZON-GEA data and a projected 45% peak penetration in its target market, Investing.com reports.

That faster ramp is the engine behind the math.

How UBS justifies a $307 target on Jazz stock

The $307 figure rests on two levers working together: higher growth and a higher multiple.

UBS now forecasts 10% revenue and 11% earnings-per-share compound annual growth from 2026 through 2030. Both run ahead of the consensus pace of roughly 7% and 6%.

Related: UBS drops aggressive Broadcom stock price forecast

On that basis, Verma argues that JAZZ deserves a richer valuation, expanding his multiple from 7 times to 10 times earnings.

In plain terms, he thinks investors should pay more for each dollar of profit because the growth looks more sustainable.

What has to go right for the Jazz Pharma bull case

• Ziihera clears its August 25 FDA review on schedule.
• The oncology ramp tracks toward UBS’s $3.1 billion peak estimate.
• Core franchises such as Xywav and Epidiolex keep growing.
• The 7x-to-10x re-rating actually sticks.

If the company misses any of these, the gap between price and target narrows fast.

What Jazz Pharma’s recent quarter shows about the setup

The upgrade did not come out of nowhere. Recent results gave UBS something concrete to build on.

Jazz reported $1.07 billion in first-quarter 2026 revenue, up 19% year over year, with adjusted earnings of $6.34 per share against a $4.66 consensus. The oncology portfolio grew 45%.

• Xywav, the lead sleep franchise, posted $408.2 million, up 18%.
• Epidiolex brought in $249.8 million in epilepsy, up 15%.
• Zepzelca surged 60% to $101 million on its lung-cancer combination. Source: Jazz Pharmaceuticals First Quarter 2026 Financial Report

Inside the Jazz Pharma revenue mix: CEO Renée Galá guided to $4.25 billion to $4.5 billion in full-year revenue and said the quarter sets the company up for a strong 2026. UBS isn’t alone in warming up, either. RBC Capital recently raised its own target to $258 from $195 while keeping an outperform rating, Investing.com notes.

How Jazz stock’s run compares to the S&P 500

To put the rally in context, it helps to measure Jazz against the broader market. While Wall Street strategists keep raising their S&P 500 targets for 2026, Jazz has run far ahead of the index.

The risks that keep Jazz Pharma from being a one-way bet

A 63% target hike is exciting, but the stock has already done a lot of the running, which limits the room for error.

The bear case is real. Xywav faces generic and Avadelcompetition over time, and Jazz carries about $5.4 billion in long-term debt.

• Top analyst drops jaw-dropping price target on Eli Lilly stock
• Hims stock price reacts strongly to crucial FDA review
• Pfizer’s newer medicines carry more weight in Q1

More health care and pharma: Insider activity adds a wrinkle. Director Bruce Cozadd sold 6,000 shares at $203.33 on May 1, according to Yahoo Finance, though much of that fell under prearranged 10b5-1 trading plans that are not necessarily a signal of sentiment.

Even so, the broader analyst consensus stays constructive, with 10 buy and seven outperform ratings against just one hold, according to MarketScreener data.

What the UBS call means for investors weighing JAZZ now

For long-term investors, the practical read is straightforward.

The UBS call rewards patience, not chasing. With shares near 52-week highs, starting small and adding around the August PDUFA decision gives you exposure to the catalyst without betting the whole position on a single FDA outcome.

The setup is genuinely improving, driven by accelerating oncology revenue and a dated near-term catalyst. The risk is that a lot of that good news is already reflected in the price.

Three things to watch before late August

• The FDA decision on Ziihera at the Aug. 25 PDUFA date
• Any NCCN guideline listing for Ziihera, which can speed adoption
• Early launch numbers, once the drug reaches the market

Those signals will tell you whether the $307 target has real footing, or whether the rally has gotten ahead of the story.

Related: Schwab flags a $1 trillion threat looming over health care